SLC9A3-AS1: A Potential Drug Target and Biomarker (G100288152)

Target Name: SLC9A3-AS1

NCBI ID: G100288152

SLC9A3-AS1

Other Name(s): SLC9A3 antisense RNA 1 | UC011CLY.2

SLC9A3-AS1: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 9 (SLC9A3) is a gene that encodes a protein known as GLUT1. GLUT1 is a transmembrane protein that is expressed in various tissues and cells throughout the body. One of its functions is to regulate the transport of glucose into the cell from the bloodstream. SLC9A3 is a single nucleotide polymorphism (SNP) gene that has been identified as a potential drug target and biomarker for various diseases.

The SLC9A3 gene has four exons, which result in a protein with four unique amino acids at its C-terminus. One of these amino acids is glutamic acid, which is known for its neuroprotective properties. The SLC9A3 protein has been shown to play a role in various cellular processes, including cell signaling, neurotransmission, and glucose metabolism.

SLC9A3 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and diabetes. Its involvement in these diseases has led to the development of new therapeutic strategies for treating these conditions. For example, SLC9A3 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This has led to the development of new drugs that target GLUT1, including GL-4012, a small molecule inhibitor of GLUT1 that is currently in clinical trials for the treatment of various cancers.

In addition to its potential as a drug target, SLC9A3 has also been identified as a potential biomarker for several diseases. Its expression has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and diabetes. This has led to the development of new diagnostic tests that can detect SLC9A3 expression, such as qRT-PCR and western blotting. These tests have the potential to aid in the diagnosis and monitoring of these diseases.

SLC9A3 has also been shown to play a role in glucose metabolism, which is a critical aspect of overall health and well-being. It has been shown to regulate the movement of glucose into the cell from the bloodstream, which is critical for maintaining proper cellular metabolism. In addition, SLC9A3 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and inflammation.

In conclusion, SLC9A3 is a gene that has been identified as a potential drug target and biomarker for various diseases. Its unique expression and involvement in cellular processes make it an attractive target for therapeutic strategies. Further research is needed to fully understand the role of SLC9A3 in disease and to develop new diagnostic tests that can aid in its detection and treatment.

Protein Name: SLC9A3 Antisense RNA 1

The "SLC9A3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9A3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets